Compare Crispr Therapeutics AG (CRSP) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Mondaycom Ltd — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $4.97B), while Mondaycom Ltd trades at $81.52 (market cap $3.51B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap. Which is the better fit depends on your goals.
| CRSP | MNDY | |
|---|---|---|
Market Cap | $4.97B | $3.51B |
Sector | Health | Technology |
52-Week High | $76.78 | $292.24 |
52-Week Low | $44.34 | $58.81 |
Enterprise Value | $3.32B | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Monday.com (MNDY) trades at $86.84, up 5.3% in the past 24 hours, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings expectations, with Q1 2026 EPS of $1.15 surpassing the $0.96 estimate. Revenue grew to $1.23 billion in 2025, though net income remained flat at $119 million year-over-year. Recent news highlights investor attention amid a 51% decline in the first half of 2026, with some viewing the dip as a buying opportunity due to solid fundamentals.
The outlook for MNDY is positive, driven by robust revenue growth, high gross margins of 89.05%, and a unanimous analyst buy consensus with a $115.50 price target. Key risks include elevated valuation multiples, competitive pressures in the SaaS space, and volatility from AI disruption concerns. Investors should weigh the company's execution against its premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
